BeOne Medicines AG (NASDAQ:ONC) is one of the most promising healthcare stocks according to Wall Street analysts.
On June 3, Citizens kept its Market Outperform rating and $396 price target on BeOne Medicines AG (NASDAQ:ONC)
The firm made the call after BeOne presented robust tumor clinical data at the American Society of Clinical Oncology (ASCO) 2026 conference. Citizens said that data for three drugs in BeOne’s pipeline caught its attention. The first was BGB-43395, which BeOne is testing in a common and hard-to-treat form of breast cancer known as HR+/HER2- metastatic breast cancer.
The other two are BG-C9074, an antibody-drug conjugate targeting ovarian cancer maintenance and BGB-B2033, a bispecific antibody that BeOne is evaluating in liver cancer. Citizens noted that in its view, what makes the pipeline noteworthy is that each of these drugs is going after patient populations where current treatments are either too toxic, face resistance problems, or simply do not exist. For that reason, the firm sees BeOne at an inflection point where its tumor strategy is no longer just theoretical.